Saunders23 |
Conventional radiotherapy: 60Gy/2Gy/30f |
225 |
- |
20%(2-year OS) |
0.004 |
acute: 7%; late: 5% |
- |
acute: 19%; late: 4%(symptomatic) |
- |
|
CHART: 1.5Gy tid, 7 days/week, a total of 54Gy |
339 |
|
29%(2-year OS) |
|
acute: 9%; late: 7% |
- |
acute: 10%; late: 16%(symptomatic) |
- |
Baumann24 |
conventional radiotherapy: 66Gy/2Gy/33f |
203 |
inoperable |
31%(2-year OS) |
0.43 |
acute: 2.2%; late;: 0.7%(≥G2) |
acute: 0.17; late: 0.62 |
acute: 9.5%; late:11%(≥G2 symptomatic) |
acute: 0.32; late: 0.59 |
|
CHART: 1.5Gy tid, 5 days/week, a total of 54Gy |
203 |
|
32%(2-year OS) |
|
acute: 5%l late: 1.9%(≥G2) |
|
acute: 6.6%; late:9.2%(≥G2 symptomatic) |
|
Mauguen25 |
Conventional radiotherapy |
2000 |
- |
15.9%(3-yearOS), 8.3%(5-year OS) |
<0.04 |
9% |
<0.001 |
- |
- |
|
CHART |
|
|
19.7%(3-yearOS), 10.8%(5-year OS) |
|
19% |
|
|
|
Din26 |
55Gy/2.67Gy/20f |
609 |
III |
50%(2-year OS) |
- |
- |
- |
15.1%(G1-2 symptomatic) |
- |
Sun27 |
conventional radiotherapy: 70.8Gy/1.86Gy/38f |
54 |
inoperable stage III |
48.1%(RR) |
0.032 |
33.3%(G2) |
- |
42.6% (≥G2) |
- |
|
hypofractionated radiotherapy: 65Gy/2.5Gy/26f |
43 |
|
69.8%(RR) |
|
25.6%(G2) |
|
34.9%(≥G2) |
|
Cannon29 |
57-85.5Gy/2.28-3.42Gy/25f |
79 |
LANSCLC |
29%(3-year OS) |
- |
acute: 48%(G2); late: 28%(G2) |
- |
16%(G2)7.6%(G4-5) |
- |
Feddock32 |
A month after standard radiotherapy to 60Gy with concurrent chemotherapy, an SBRT boost was given in ≤5cm residual primary tumors: 10Gy×2f for peripheral lesions, 6.5Gy×3f for central lesions |
61 |
II/III |
82.9%(primary tumor control with a median follow-up of 13 months) |
- |
1.6%(G2) |
- |
acute:17.1%; late: 9.4%(≥G2) |
- |
Karam33 |
An SBRT boost with 20-30Gy over 5 fractions was prescribed after conventional CCRT to a median dose of 50.4Gy |
16 |
LANSCLC , |
78%(1-yearOS) 76%(1-yearLRC) |
- |
18% (G2) |
- |
25% (G2) |
- |
Higgins34 |
Standard radiotherapy to 44Gy with concurrent chemotherapy, followed by an SBRT boost in the lung and nodal residuals in four groups: 9Gy×2f, 10Gy×2f, 6Gy×5f and 7Gy×5f |
19 |
stageIII(N1/ N2) with ,primary tumors ≤8cm and lymph nodes ≤5cm |
39%(3-yearOS) 59%(3-yearLRC) |
- |
- |
- |
- |
- |
Hepel35 |
Standard radiotherapy to 50.4Gy with concurrent chemotherapy, followed by an SBRT boost in the lung and nodal residuals in four groups: 8Gy×2f, 10Gy×2f, 12Gy×2f and 14Gy×2f |
12 |
Stage II/III with primary tumor ≤120cc and lymph node volume ≤ 60cc |
78%(1-yearLRC) |
- |
0(≥G3) |
- |
acute: 0(≥G3); late: 8.33%(G5) |
- |